The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11150 malaria professionals are enjoying the free benefits of MalariaWorld today


Not Open Access | Effectiveness of artesunate–amodiaquine vs. artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in Nanoro, Burkina Faso: a non-inferiority randomised trial

April 2, 2014 - 18:23 -- NOT Open Access
Halidou Tinto, Salou Diallo, Umberto D'Alessandro, et al.
Tropical Medicine & International Health, Volume 19, Issue 4, pages 469–475, April 2014

We report here the results of a study assessing the effectiveness of the two ACTs currently recommended in Burkina Faso for the treatment of uncomplicated malaria, that is, artemether–lumefantrine (AL) and artesunate–amodiaquine (ASAQ).

Not Open Access | The survival times of malaria-infected mice are prolonged more by several new two-carbon-linked artemisinin-derived dimer carbamates than by the trioxane antimalarial drug artemether

February 26, 2014 - 16:28 -- NOT Open Access
Ryan C. Conyers, Jennifer R. Mazzone, Maxime A. Siegler, Abhai K. Tripathi, David J. Sullivan, Bryan T. Mott, Gary H. Posner
Bioorganic & Medicinal Chemistry Letters, Volume 24, Issue 5, 1 March 2014, Pages 1285-1289

This ACT chemotherapy result is of high medicinal significance because the antimalarial efficacy of the popular trioxane drug artemether (2) plus mefloquine under the same conditions was significantly lower (only 20 day average survival). 

Scale-up of Malaria Rapid Diagnostic Tests and Artemisinin-Based Combination Therapy: Challenges and Perspectives in Sub-Saharan Africa

February 4, 2014 - 18:48 -- Open Access
Guido J. H. Bastiaens, Teun Bousema, Toby Leslie
PLoS Med 11(1): e1001590

In this Policy Forum article we examine the operational challenges to implementing the T3 strategy of scaling up and maintaining RDT coverage. We identify gaps in planning for at-scale implementation in policy design and implementation, the local health care setting, and the attitudes and demands of patients.


Not Open Access | Prevailing Plasmodium falciparum dihydrofolate reductase 108-asparagine in Hodeidah, Yemen: A questionable sulfadoxine–pyrimethamine partner within the artemisinin-based combination therapy

February 4, 2014 - 18:39 -- NOT Open Access
Rashad Abdul-Ghani, Hoda F. Farag, Amal F. Allam, Sherine M. Shawky
Acta Tropica, Volume 132, April 2014, Pages 39-44

The dhfr 108N was detected among about 61% of P. falciparum isolates, in its pure and mixed-type forms, from Hodeidah. Age, gender and residence of patients were not significant predictors for the presence of the mutant allele among parasite isolates.

Not Open Access | What determines providers' stated preference for the treatment of uncomplicated malaria?

January 22, 2014 - 14:46 -- NOT Open Access
Lindsay Mangham-Jefferies, Kara Hanson, Wilfred Mbacham, Obinna Onwujekwe, Virginia Wiseman
Social Science & Medicine, Volume 104, March 2014, Pages 98-106

518 providers working at non-profit health facilities and for-profit pharmacies and drug stores in Yaoundé and Bamenda in Cameroon and in Enugu State in Nigeria were surveyed between July and December 2009 to elicit the antimalarial they prefer to supply for uncomplicated malaria.

Not Open Access | Validation of ELISA for Quantitation of Artemisinin-Based Antimalarial Drugs

December 11, 2013 - 17:54 -- NOT Open Access
Min Wang, Yongliang Cui, Guofa Zhou, Guiyun Yan, Liwang Cui and Baomin Wang
Am J Trop Med Hyg 2013 89:1122-1128

Our results showed that the icELISA has the potential to be improved for quality assurance of ARTs at the point of care in endemic settings.

Artemisinin Combination Therapy: A Good Antimalarial, but Is the Dose Right?

December 10, 2013 - 06:52 -- Open Access
Paul Garner
PLoS Med 10(12): e1001565

Artemisinin combination therapy (ACT) has revolutionised malaria treatment. ACTs combine an artemisinin derivative (a relatively new group of very effective drugs  with another longer-lasting drug from another class to try to reduce the risk of further resistance developing. ACTs cure over 90% of people; they also act against malaria gametocytes, so potentially reduce transmission.

Not Open Access | Development of solid dispersions of artemisinin for transdermal delivery

October 29, 2013 - 17:33 -- NOT Open Access
Yasser Shahzad, Sadia Sohail, Muhammad Sohail Arshad, Talib Hussain, Syed Nisar, Hussain Shah
International Journal of Pharmaceutics, Volume 457, Issue 1, 30 November 2013, Pages 197-205

Formulations were characterised using a combination of molecular dynamics (MD) simulations, differential scanning calorimetry (DSC), X-ray diffraction (XRD) and Fourier transform infrared spectroscopy (FT-IR).

Blocking malaria transmission to Anopheles mosquitoes using artemisinin derivatives and primaquine: a systematic review and meta-analysis

October 17, 2013 - 15:23 -- Open Access
Solomon Mequanente Abay
Parasites & Vectors 2013, 6 :278 (24 September 2013)

The present study aimed to assess evidence for this hypothesis from controlled trials.

Not Open Access | Synthesis of artemisinin dimers using the Ugi reaction and their in vitro efficacy on breast cancer cells

July 18, 2013 - 17:51 -- NOT Open Access
Shusheng Wang, Tomikazu Sasaki
Bioorganic & Medicinal Chemistry Letters, Volume 23, Issue 15, 1 August 2013, Pages 4424-4427

The Ugi four-component reaction was used to prepare a series of artemisinin monomers and dimers. We found that the endoperoxide group in artemisinin remains intact during the reaction.


Subscribe to RSS - artemisinin